Dexchlorpheniramine Maleate

證據等級: L5

預測適應症: 1 個

Dexchlorpheniramine Maleate: From Allergic Conditions to Acute Intermittent Porphyria

One-Sentence Summary

Dexchlorpheniramine maleate is a first-generation H1 antihistamine, widely used for the symptomatic relief of allergic conditions such as allergic rhinitis and urticaria. The TxGNN model predicts it may be effective for Acute Intermittent Porphyria (AIP), a rare inherited metabolic disorder. Currently, there are no clinical trials and no direct publications supporting this specific drug-disease combination, though indirect mechanistic evidence from related antihistamines and preclinical porphyria models provides a scientific basis for further investigation.

Quick Overview

Item	Content
Original Indication	Allergic conditions (antihistamine)
Predicted New Indication	Acute Intermittent Porphyria
TxGNN Prediction Score	99.12%
Evidence Level	L4 — Preclinical / mechanism-based evidence (indirect)
Malaysia Market Status	✓ Marketed
Number of Registrations	18
Recommended Decision	Hold

Why is This Prediction Reasonable?

Dexchlorpheniramine is the dextrorotatory isomer of chlorpheniramine and acts as a potent first-generation H1 histamine receptor antagonist. It competitively blocks H1 receptors on effector cells, thereby suppressing histamine-mediated allergic responses including vasodilation, increased vascular permeability, and pruritus.

The link between antihistamines and porphyria, while indirect, has emerging scientific support. A 2025 study by Kuo et al. published in Cellular and Molecular Gastroenterology and Hepatology demonstrated for the first time that the histamine pathway is directly involved in protoporphyrin accumulation and hepatic injury: (1) histamine increases protoporphyrin IX (PP-IX) accumulation; (2) H1/H2 receptor blockade reduces PP-IX concentrations; and (3) chlorcyclizine, a structurally related first-generation H1 antihistamine, significantly ameliorated liver injury in an erythropoietic protoporphyria (EPP) mouse model. Furthermore, the H2 antihistamine cimetidine has over 35 years of case report history in AIP treatment, although its proposed mechanism has since been revised.

However, important caveats must be noted. Most preclinical data pertain to EPP rather than AIP, and these two porphyrias have distinct pathophysiological mechanisms. The true therapeutic mechanism of cimetidine in AIP remains unclear, and there is no direct evidence for dexchlorpheniramine itself in AIP. On the positive side, first-generation H1 antihistamines are classified as “safe / probably safe” in acute porphyria, and dexchlorpheniramine is a CYP2D6 substrate/inhibitor rather than an inducer, meaning it does not carry porphyrinogenic risk.

Clinical Trial Evidence

Currently no related clinical trials registered for the combination of dexchlorpheniramine and acute intermittent porphyria.

Literature Evidence

Currently no direct literature available for the combination of dexchlorpheniramine and acute intermittent porphyria.

Note: While no direct publications exist for this specific drug-disease pair, the following related references inform the mechanistic rationale:

Kuo et al. (2025), Cell Mol Gastroenterol Hepatol — demonstrated histamine pathway involvement in protoporphyrin accumulation and hepatic injury, with H1 antihistamine (chlorcyclizine) showing benefit in EPP mouse models.
Historical case reports (>35 years) of cimetidine (H2 antihistamine) use in AIP management.

Malaysia Market Information

Dexchlorpheniramine maleate has 18 registered products in Malaysia with market status: Marketed.

Detailed license information (authorization numbers, product names, dosage forms, and approved indications) is currently unavailable in the evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Note on Porphyria Safety: First-generation H1 antihistamines, including dexchlorpheniramine, are generally classified as “safe / probably safe” for use in patients with acute porphyria. Dexchlorpheniramine is a CYP2D6 substrate/inhibitor and is not a CYP enzyme inducer, which means it does not carry porphyrinogenic risk — an important consideration for any drug being evaluated for use in porphyria patients.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction score is high (99.12%), and there is a plausible, albeit indirect, mechanistic link via the histamine–protoporphyrin pathway demonstrated in preclinical EPP models. However, there are no clinical trials, no direct publications, and no direct evidence for dexchlorpheniramine in AIP specifically. The mechanistic evidence largely derives from a related porphyria subtype (EPP) and from different antihistamines (chlorcyclizine, cimetidine), making extrapolation premature.

To proceed, the following is needed:

Mechanism of action data (MOA): Retrieve detailed pharmacological data from DrugBank to clarify receptor binding profiles and downstream effects relevant to heme biosynthesis
Safety profile: Obtain package insert warnings and contraindications from the Malaysian NPRA or equivalent regulatory source
Preclinical validation: In vitro or in vivo studies testing dexchlorpheniramine specifically in AIP models (not just EPP)
Literature deep-dive: Systematic review of all antihistamines (H1 and H2) studied in any porphyria subtype, to map the class-level evidence landscape
Consultation with porphyria specialists: Expert opinion on whether H1 blockade could address the HMBS enzyme deficiency and ALA/PBG accumulation that characterize AIP, as opposed to the FECH deficiency in EPP
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.